Liaskas A, Dimopoulou M, Piperidou A, Angelopoulou M, Vassilakopoulos T
J Clin Med. 2025; 14(4).
PMID: 40004722
PMC: 11856677.
DOI: 10.3390/jcm14041191.
Chen W, Zhang Z
Onco Targets Ther. 2025; 18():1-14.
PMID: 39802262
PMC: 11720807.
DOI: 10.2147/OTT.S487088.
Kato K, Nakamura S, Wakana A, Koh Y, Izutsu K
Int J Clin Oncol. 2024; 29(12):1977-1983.
PMID: 39294486
DOI: 10.1007/s10147-024-02627-8.
Dourthe M, Auperin A, Rigaud C, Barbati M, Bonneau J, Buchbinder N
Haematologica. 2024; 109(11):3790-3794.
PMID: 38988265
PMC: 11532712.
DOI: 10.3324/haematol.2024.285403.
Tan J, Zhong J, Hu W, Wu G, Zeng C, Xiong D
J Int Med Res. 2024; 52(6):3000605241258597.
PMID: 38869106
PMC: 11179474.
DOI: 10.1177/03000605241258597.
Beyond Chemotherapy: Present and Future Perspectives in the Treatment of Lymphoproliferative Disorders.
Massaro F, Andreozzi F, Abrassart T, Castiaux J, Massa H, Rizzo O
Biomedicines. 2024; 12(5).
PMID: 38790939
PMC: 11117538.
DOI: 10.3390/biomedicines12050977.
Nivolumab combined with brentuximab vedotin with or without mediastinal radiotherapy for relapsed/refractory primary mediastinal large B-cell lymphoma.
Renaud L, Wencel J, Pages A, Al Jijakli A, Moatti H, Quero L
Haematologica. 2024; 109(9):3019-3023.
PMID: 38695142
PMC: 11367187.
DOI: 10.3324/haematol.2023.284689.
[Progress in treatment of primary mediastinal large B-cell lymphoma].
Chen L, Li J, Fan L
Zhonghua Xue Ye Xue Za Zhi. 2024; 45(1):98-102.
PMID: 38527847
PMC: 10951116.
DOI: 10.3760/cma.j.cn121090-20230731-00041.
Mature B-cell lymphomas in adolescents and young adults.
El-Mallawany N, Giulino-Roth L, Burke J, Hermiston M, Allen C
EJHaem. 2023; 4(4):912-920.
PMID: 38024628
PMC: 10660408.
DOI: 10.1002/jha2.783.
Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas.
Katsuya H, Suzumiya J, Kimura S
Cancers (Basel). 2023; 15(22).
PMID: 38001659
PMC: 10670854.
DOI: 10.3390/cancers15225399.
Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates.
Fu Z, Gao C, Wu T, Wang L, Li S, Zhang Y
iScience. 2023; 26(10):107778.
PMID: 37727735
PMC: 10505985.
DOI: 10.1016/j.isci.2023.107778.
Harnessing the Immune System: An Effective Way to Manage Diffuse Large B-Cell Lymphoma.
Visweshwar N, Rico J, Killeen R, Manoharan A
J Hematol. 2023; 12(4):145-160.
PMID: 37692863
PMC: 10482611.
DOI: 10.14740/jh1112.
Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up.
Zinzani P, Santoro A, Gritti G, Brice P, Barr P, Kuruvilla J
Blood Adv. 2023; 7(18):5272-5280.
PMID: 37352266
PMC: 10500465.
DOI: 10.1182/bloodadvances.2023010254.
Efficacy and safety of geptanolimab (GB226) for relapsed/refractory primary mediastinal large B-cell lymphoma: an open-label phase II study (Gxplore-003).
Shi Y, Cui J, Zhou H, Zhang X, Zou L, Cao J
Cancer Immunol Immunother. 2023; 72(9):2991-3002.
PMID: 37289256
PMC: 10992796.
DOI: 10.1007/s00262-023-03467-7.
Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170.
Zinzani P, Thieblemont C, Melnichenko V, Bouabdallah K, Walewski J, Majlis A
Blood. 2023; 142(2):141-145.
PMID: 37130017
PMC: 10651864.
DOI: 10.1182/blood.2022019340.
Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives.
Prince H, Hutchings M, Domingo-Domenech E, Eichenauer D, Advani R
Ann Hematol. 2022; 102(1):13-29.
PMID: 36512081
PMC: 9807535.
DOI: 10.1007/s00277-022-05054-9.
Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab.
Papageorgiou S, Thomopoulos T, Liaskas A, Vassilakopoulos T
Cancers (Basel). 2022; 14(8).
PMID: 35454825
PMC: 9026383.
DOI: 10.3390/cancers14081917.
Prognostic significance of clinical characteristics and Fluorodeoxyglucose-positron emission tomography/computed tomography quantitative parameters in patients with primary mediastinal B-cell lymphoma.
Liu Y, Jiang J, Liu L, Wang Z, Yu B, Xia Z
J Int Med Res. 2022; 50(1):3000605211063027.
PMID: 35001690
PMC: 8743955.
DOI: 10.1177/03000605211063027.
Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders.
Mihalyova J, Hradska K, Jelinek T, Motais B, Celichowski P, Hajek R
Int J Mol Sci. 2021; 22(21).
PMID: 34768899
PMC: 8584080.
DOI: 10.3390/ijms222111470.
Current and emerging treatment options in primary mediastinal B-cell lymphoma.
Fakhri B, Ai W
Ther Adv Hematol. 2021; 12:20406207211048959.
PMID: 34659697
PMC: 8511915.
DOI: 10.1177/20406207211048959.
